Compositions and methods for detection of mycobacterium tuberculosis

• US 9,970,062 B2
• Filed: 08/06/2015
• Issued: 05/15/2018
• Est. Priority Date: 08/06/2015
• Status: Active Grant

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Roche Molecular Systems (Roche Holding AG)
• Inventors: Johnson, Jenny A.
• Primary Examiner(s): SITTON, JEHANNE SOUAYA
• Application Number:
  US14/819,427
• Publication Number:
  US 20170037452A1
• Time in Patent Office: 1,013 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Method for the rapid detection of the presence or absence of Mycobacterium tuberculosis (MTB) and other members of the MTB-complex in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the esxJ gene, along with kits are provided that are designed for the detection of MTB.

Claims

1. A method of detecting Mycobacterium tuberculosis (MTB) and other members of the MTB-complex in a sample, the method comprising:

performing an amplifying step comprising contacting the sample with a set of esxJ primers to produce an amplification product if a esxJ nucleic acid is present in the sample;

performing a hybridizing step comprising contacting the amplification product with one or more detectable esxJ probes; and

detecting the presence or absence of the amplification product, wherein the presence of the amplification product is indicative of the presence of MTB in the sample and wherein the absence of the amplification product is indicative of the absence of MTB in the sample;

wherein the set of esxJ primers comprise a first primer consisting of SEQ ID NO;

1, or the complement thereof, and optionally having at least one modified nucleotide, or SEQ ID NO;

7, or the complement thereof, and optionally having at least one modified nucleotide, or SEQ ID NO;

8, or the complement thereof, and optionally having at least one modified nucleotide; and

a second primer consisting of SEQ ID NO;

15, or the complement thereof, and optionally having at least one modified nucleotide, or SEQ ID NO;

16, or the complement, thereof and optionally having at least one modified nucleotide, or SEQ ID NO;

17, or the complement thereof, and optionally having at least one modified nucleotide; and

wherein one of the one or more detectable esxJ probes consists of SEQ ID NO;

30, or the complement thereof, and optionally having at least one modified nucleotide, at least one label, and at least one quencher moiety;

and wherein the set of esxJ primers and the one or more detectable esxJ probes used in combination do not amplify and/or detect non-MTB species in the sample.

2. The method of claim 1, wherein:

the hybridizing step comprises contacting the amplification product with the detectable esxJ probe that is labeled with a donor fluorescent moiety and a corresponding acceptor moiety; and

the detecting step comprises detecting the presence or absence of fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor moiety of the probe, wherein the presence or absence of fluorescence is indicative of the presence or absence of MTB in the sample.

3. The method of claim 2, wherein said amplification step employs a polymerase enzyme having 5′

to 3′

nuclease activity.

4. The method of claim 2, wherein the acceptor moiety is a quencher.

5. The method of claim 1, wherein any one of the set of esxJ primers and the one or more detectable esxJ probes comprise at least one modified nucleotide.

6. The method of claim 5, wherein the at least one modified nucleotide is selected from t-butylbenzyldeoxyadenine or t-butylbenzyldeoxycytosine.

7. The method of claim 1 wherein the first primer consists of SEQ ID NO:

1, and contains t-butylbenzyldeoxyadenine on its 3′

terminal nucleotide.

8. The method of claim 1 wherein the first primer consists of SEQ ID NO:

7 and contains t-butylbenzyldeoxycytosine on its 3′

terminal nucleotide.

9. The method of claim 1 wherein the first primer consists of SEQ ID NO:

8 and contains t-butylbenzyldeoxycytosine on its 3′

terminal nucleotide.

10. The method of claim 1 wherein the second primer consists of SEQ ID NO:

15 and contains t-butylbenzyldeoxycytosine on its 3′

terminal nucleotide.

11. The method of claim 1 wherein the second primer consists of SEQ ID NO:

16 and contains t-butylbenzyldeoxycytosine on its 3′

terminal nucleotide.

12. The method of claim 1 wherein the second primer consists of SEQ ID NO:

17 and contains t-butylbenzyldeoxycytosine on its 3′

terminal nucleotide.